3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
121
Breast Neoplasms
83
Colorectal Neoplasms
52
Stomach Neoplasms
42
Pancreatic Neoplasms
42
Lung Neoplasms
41
Rectal Neoplasms
38
Neoplasm Metastasis
36
Neoplasms
33
Esophageal Squamous Cell Carcinoma
32
Esophageal Neoplasms
31
Head and Neck Neoplasms
26
Squamous Cell Carcinoma of Head and Neck
23
Ovarian Neoplasms
23
Triple Negative Breast Neoplasms
21
Nasopharyngeal Carcinoma
20
Recurrence
18
Leukemia, Myeloid, Acute
18
Colonic Neoplasms
18
Uterine Cervical Neoplasms
17
Precursor Cell Lymphoblastic Leukemia-Lymphoma
17
Small Cell Lung Carcinoma
15
Glioblastoma
15
Lymphoma
12
Prostatic Neoplasms
11
Fallopian Tube Neoplasms
11
Carcinoma, Squamous Cell
11
Brain Neoplasms
11
Sarcoma
10
NSCLC
9
Interventions
Everolimus
5
Cetuximab
2
volagidemab
1
tanezumab
1
pembrolizumab
1
inavolisib
1
Vemurafenib
1
Trimetazidine
1
Sirolimus
1
Secretin
1
SF 1126
1
Pharmaceutical Preparations
1
Panobinostat
1
Oxaliplatin
1
Nivolumab
1
NVP-BKM120
1
Leucovorin
1
Irinotecan
1
Fulvestrant
1
Fluorouracil
1
Drug Therapy
1
Capecitabine
1
CB-839
1
CA-19-9 Antigen
1
Bevacizumab
1
Aspirin
1
Alpelisib
1
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Hereditary Sensory and Autonomic Neuropathies
×
Drug Therapy
×
Clear all
NCT03386162
2022-11-28
SAFIR-PI3K
UNICANCER
Phase 2
Terminated
31 enrolled